KURA ONCOLOGY INC. -

Kura Oncology to Participate in JMP Securities Hematology and Oncology Summit

25 Nov 2024 07:30:00 By Nasdaq GlobeNewswire

Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias

20 Nov 2024 17:00:00 By Nasdaq GlobeNewswire

Kura Oncology Reports Third Quarter 2024 Financial Results

07 Nov 2024 16:05:01 By Nasdaq GlobeNewswire

Kura Oncology to Present Updated Data from KOMET-007 Combination Trial of Ziftomenib at ASH Annual Meeting

05 Nov 2024 09:09:54 By Nasdaq GlobeNewswire

Kura Oncology to Report Third Quarter 2024 Financial Results

31 Oct 2024 07:30:00 By Nasdaq GlobeNewswire

Kura Oncology Reports Preclinical Data Supporting Opportunity for Ziftomenib in Treatment of Gastrointestinal Stromal Tumors (GIST)

24 Oct 2024 07:30:00 By Nasdaq GlobeNewswire

Kura Oncology to Present New Data Supporting Combination of KO-2806 with KRAS G12C and Pan-RAS Inhibitors

23 Oct 2024 07:30:00 By Nasdaq GlobeNewswire

Kura Oncology Announces Publication of Ziftomenib Phase 1 Results in The Lancet Oncology

30 Sep 2024 18:30:00 By Nasdaq GlobeNewswire

Kura Oncology Appoints Michael Vasconcelles, M.D., to Board of Directors

17 Sep 2024 07:30:00 By Nasdaq GlobeNewswire

Kura Oncology to Participate in Cantor Global Healthcare Conference

10 Sep 2024 07:30:00 By Nasdaq GlobeNewswire

Kura Oncology Reports Second Quarter 2024 Financial Results

08 Aug 2024 16:05:00 By Nasdaq GlobeNewswire

Kura Oncology Announces FDA Clearance of IND Application for Menin Inhibitor Ziftomenib in Advanced Gastrointestinal Stromal Tumors (GIST)

08 Aug 2024 07:30:00 By Nasdaq GlobeNewswire

Kura Oncology to Report Second Quarter 2024 Financial Results

01 Aug 2024 07:30:00 By Nasdaq GlobeNewswire

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 Jul 2024 07:30:00 By Nasdaq GlobeNewswire

Kura Oncology Reports Preclinical Data Supporting Potential for Menin Inhibitor in Diabetes

24 Jun 2024 07:30:00 By Nasdaq GlobeNewswire

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

07 Jun 2024 07:30:00 By Nasdaq GlobeNewswire

Kura Oncology to Participate in Jefferies Global Healthcare Conference

29 May 2024 07:30:00 By Nasdaq GlobeNewswire

Kura Oncology Completes Enrollment in Registration-Directed Trial of Ziftomenib in NPM1-Mutant AML

14 May 2024 07:30:00 By Nasdaq GlobeNewswire

Kura Oncology to Participate in Bank of America Securities Healthcare Conference

08 May 2024 07:30:00 By Nasdaq GlobeNewswire

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 May 2024 07:30:00 By Nasdaq GlobeNewswire